NASDAQ · FRTX
Healthcare · Biotechnology
$0.94
Down-$0.01 (-0.53%)
Updated Aug 16, 2026, 1:40 PM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 0 trading sessions · Daily adjusted prices
FRTX does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
The latest Smart Investors Daily articles mentioning FRTX.
FRTX research
Company profile and research snapshot.
Fresh Tracks Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the development of various prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases in the United States. The company develops sofpironium bromide, which has completed Phase III clinical trials for the treatment of primary axillary hyperhidrosis; BBI-02, an oral DYRK1A inhibitor for the treatment of autoimmune and inflammatory diseases; and BBI-10, a covalent stimulator of interferon genes inhibitor for the potential treatment of autoinflammatory and rare genetic diseases, as well as next-generation kinase inhibitors. It has license and collaboration agreements with Carna Biosciences, Inc., Voronoi Inc., Bodor Laboratories, Inc. and Dr. Nicholas S. Bodor, and AnGes, Inc. The company was formerly known as Brickell Biotech, Inc. and changed its name to Fresh Tracks Therapeutics, Inc. in September 2022. Fresh Tracks Therapeutics, Inc. was founded in 2009 and is headquartered in Boulder, Colorado.
Visit company websiteConsensus and target data currently published for this company.
No generated briefing is available yet.
Benzinga · Feb 25, 2025
Fresh Tracks Therapeutics announced its planned dissolution, an initial cash distribution to shareholders, and the termination of trading on the OTC Pink Market. The company is winding down operations and resolving outstanding liabilities.
Benzinga · Jan 27, 2025
Fresh Tracks Therapeutics announced that the Court of Chancery of the State of Delaware has appointed its CEO and CFO as the custodian to dissolve the company and distribute between $0.95 and $0.98 per share to stockholders in the first quarter of 2024.
GlobeNewswire Inc. · Jun 17, 2024
Company filed an answer in overall agreement with petition on June 14, 2024 and awaits a hearing date from the Delaware Chancery Court Company filed an answer in overall agreement with petition on June 14, 2024 and awaits a hearing date from the Delaware Chancery Court
GlobeNewswire Inc. · Dec 19, 2023
BOULDER, Colo., Dec. 19, 2023 (GLOBE NEWSWIRE) -- Fresh Tracks Therapeutics, Inc. (OTC Pink: FRTX) (“Fresh Tracks” or the “Company”) announced today that the Company’s common stock was suspended from trading on The Nasdaq Capital Market at the open of business. Following the suspension, the Company’s common stock now is quoted on the OTC Pink market under the same trading symbol, “FRTX.” The Company has withdrawn its appeal of Nasdaq’s determination to delist the Company’s common stock, which will no longer trade on The Nasdaq Capital Market.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning FRTX.
No results
No recent SID articles mention FRTX.
